A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which ...

New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.